Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Philippe Moreau, Tamás Masszi, Norbert Grząśko, +23

New England Journal of Medicine

Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain

Lixin Sun, Ai-Min Hui, Qin Su, +10

Cancer Cell

Neuro-oncologyNeuroregenerationAngiogenesisDevelopmental BiologyGlioma +8

Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy

Guido Torzilli, Masami Minagawa, Tadatoshi Takayama, +5

Hepatology

Surgical OncologyDiagnosisPathologyInterventional RadiologySurgery +18

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky, +16

The Lancet Oncology

Hematological MalignancyMedicineHematologyClinical TrialsImmunology +8

The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas

Yae Kanai, Saori Ushijima, Ai-Min Hui, +4

International Journal of Cancer

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Paul G. Richardson, Rachid Baz, Michael Wang, +11

Blood

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Shaji Kumar, William Bensinger, Todd M. Zimmerman, +9

Blood

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, +12

Blood

Liver Injury Following Normothermic Ischemia in Steatotic Rat Liver

Ai-Min Hui, Seiji Kawasaki, Masatoshi Makuuchi, +3

Hepatology

Agents with Selective Estrogen Receptor (ER) Modulator Activity Induce Apoptosis<b><i>In vitro</i></b>and<b><i>In vivo</i></b>in ER-Negative Glioma Cells

Ai-Min Hui, Wei Zhang, Wei Chen, +4

Cancer Research